The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / 2014 ACR/ARHP Annual Meeting: Autoimmune Connective Tissue Diseases and Cancer

2014 ACR/ARHP Annual Meeting: Autoimmune Connective Tissue Diseases and Cancer

April 1, 2015 • By Susan Bernstein

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Cancer immunoediting includes three phases: elimination, equilibrium and escape. Early on, the body senses cancer and offers a potent immune response to eliminate it. “But cancer didn’t get to be where cancer is by being nonplastic, nondynamic or unable to evolve. Cancer will do everything it can to shake that negative force,” said Dr. Rosen. During equilibrium, cancer cells move, and the immune response follows to fight it—a highly dynamic and plastic process. However, the cancer is not gone, but unable to grow and spread due to the immune forces. As time goes by, cancer may become more mutated, dealing the immune system a “death blow,” and escape to cause damage, Dr. Rosen said.

You Might Also Like
  • 2014 ACR/ARHP Annual Meeting: Super Proteins Eyed in Therapies for Rheumatic Diseases
  • 2014 ACR/ARHP Annual Meeting: Sjögren’s Complications
  • 2015 ACR/ARHP Annual Meeting: Role of Tumor Necrosis Factor Cytokines in Autoimmune Diseases Examined
Explore This Issue
April 2015
Also By This Author
  • The ACR Debuts Open Access Journal

In systemic sclerosis patients with autoantibodies to POLR3 (RNA polymerase III), the immune response may be due to a mutated autoantigen, said Dr. Rosen. Immunoediting occurs in human tumors as a potent anticancer mechanism, and this mechanism may help protect these patients by either killing the cancer or keeping it in the equilibrium phase, he said.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Susan Bernstein is a freelance medical journalist based in Atlanta.

Second Chance

If you missed this session, it’s not too late. Catch it on SessionSelect.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 | Single Page

Filed Under: Meeting Reports Tagged With: ACR/ARHP Annual Meeting, Autoimmune, Bernstein, Cancer, connective tissue disease, malignancy, patient care, rheumatology, screeningIssue: April 2015

You Might Also Like:
  • 2014 ACR/ARHP Annual Meeting: Super Proteins Eyed in Therapies for Rheumatic Diseases
  • 2014 ACR/ARHP Annual Meeting: Sjögren’s Complications
  • 2015 ACR/ARHP Annual Meeting: Role of Tumor Necrosis Factor Cytokines in Autoimmune Diseases Examined
  • 2015 ACR/ARHP Annual Meeting: T Follicular Helper Cells Emerge as Potential Treatment Target for Autoimmune Diseases

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.